As many of you have already heard here in the forum and elsewhere, Dr. Ola Landgren, who is currently Chief of the Multiple Myeloma Section at the National Cancer Institute (NCI), will be moving to Memorial Sloan Kettering in New York City, effective May 1 of this year.
Many Beacon readers follow Dr. Landgren's research closely. Some have even participated in clinical trials at the NCI (National Institutes of Health) that have been led by Dr. Landgren.
The Beacon also turns to Dr. Landgren regularly for insights into research he's been involved with, and for comments on research by other myeloma specialists in fields related to Dr. Landgren's own areas of focus.
Thus, we thought we would share with you the announcement the NCI sent to members of its staff about Dr. Langren's move to Sloan Kettering. The announcement has been provided to The Beacon courtesy of Dr. Landgren, who forwarded it to us thinking it might be of interest (and use) to Beacon readers.
The text of the announcement is as follows:
Ola Landgren, MD, PhD, Senior Investigator & Chief of the Multiple Myeloma Section, Lymphoid Malignancies Branch (formally, Metabolism Branch), NCI, has accepted a new position at Memorial Sloan-Kettering Cancer Center (MSKCC), in New York City. Dr. Landgren will serve as Attending Physician and Chief of the Myeloma Service, Division of Hematologic Oncology and as a Member, Memorial Hospital. He will also be proposed to a parallel academic appointment as Professor of Medicine at the Weill Cornell Medical College. Dr. Landgren will start his new endeavor on May 1, 2014.
Dr. Landgren is an international leader in the myeloma field. He transferred to the Center for Cancer Research in February, 2009 from the Division of Cancer Epidemiology & Genetics (DCEG), where he had established a productive research program centered on the molecular epidemiology of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance (MGUS). While at CCR, Dr. Landgren expanded his research effort to the bedside with the focus on developing targeted strategies to delay, prevent and cure these diseases. He has pioneered the field of advanced treatment and minimal residual disease monitoring in the setting of smoldering myeloma, with the mission to find a cure. Dr. Landgren developed, implemented and enrolled patients on 14 investigator-initiated phase I/II clinical trials focusing on early myeloma (MGUS and smoldering myeloma), as well as newly-diagnosed and relapsed myeloma. His dedication to his patients and his drive to provide them with better treatments has been strong and consistent and he has published 143 peer-reviewed papers in that time, including 11 as first author and 74 as senior author. He received NIH tenure in 2011.
During his time at CCR, Dr. Landgren has been active across the CCR community, both in his many scientific collaborations and in his leadership roles, such as Chair of the Scientific Review Committee for the Medical Oncology Branch, member of the CCR Clinical Research Strategic Planning Committee, and the CCR Grand Rounds Planning Committee, and NCI Representative on the Myeloma Steering Committee, Hematologic Malignancies Program, CTEP, DCTD.
We are very fortunate that Dr. Landgren will maintain his scientific collaborations with NCI and the NIH community. Please join us in congratulating him on this new opportunity and thanking him for his work and collegiality during his time at CCR.
Bob Wiltrout, PhD, Director, CCR
Lee Helman, MD, Scientific Director for Clinical Research
- - - - - - - - - - - -
Please join The Beacon in wishing Dr. Landgren a smooth transition to his new position at Memorial Sloan Kettering, and continued success with the research he and his colleagues are doing.
Forums
5 posts
• Page 1 of 1
Re: Dr. Ola Landgren & Memorial Sloan Kettering
He is one of the nicest and most brilliant persons I have ever met. I am lucky to have him as my doctor and I intend to follow him to Sloan. Terry l.
-
terryl1 - Name: Terry
- Who do you know with myeloma?: self
- When were you/they diagnosed?: August 10, 2011
- Age at diagnosis: 49
Re: Dr. Ola Landgren & Memorial Sloan Kettering
Dr. Landgren is a dedicated researcher, an excellent physician and a caring person. I also intend to follow him to NY.
-
Reina W
Re: Dr. Ola Landgren & Memorial Sloan Kettering
Hi,
I am very interested in Dr Landgren's work. How would we go about to get him to treat my husband?
We live in Norway, where my husband had an ASCT in March 2013. He has been in great shape since then, but now his light chain levels are starting to increase again. We want to try and be better prepared this time, and have a good plan for his next round of treatment.
How should we approach Memorial Sloan Kettering? Do they have research programmes that one can apply to? I would be very grateful for any advice.
Best wishes,
Grethe
I am very interested in Dr Landgren's work. How would we go about to get him to treat my husband?
We live in Norway, where my husband had an ASCT in March 2013. He has been in great shape since then, but now his light chain levels are starting to increase again. We want to try and be better prepared this time, and have a good plan for his next round of treatment.
How should we approach Memorial Sloan Kettering? Do they have research programmes that one can apply to? I would be very grateful for any advice.
Best wishes,
Grethe
-
gretheo
Re: Dr. Ola Landgren & Memorial Sloan Kettering
Hello Grethe,
The telephone number for the multiple myeloma clinic at Memorial Sloan-Kettering -- the cancer center where Dr. Landgren is now located -- is +1 646 497-9062.
The home page for the clinic is:
http://www.mskcc.org/cancer-care/adult/multiple-myeloma
As you will see, there is a link on that page labeled "Our Clinical Trials" that will take you to a list of the myeloma-related clinical trials Sloan-Kettering is participating in (or leading).
The telephone number for the multiple myeloma clinic at Memorial Sloan-Kettering -- the cancer center where Dr. Landgren is now located -- is +1 646 497-9062.
The home page for the clinic is:
http://www.mskcc.org/cancer-care/adult/multiple-myeloma
As you will see, there is a link on that page labeled "Our Clinical Trials" that will take you to a list of the myeloma-related clinical trials Sloan-Kettering is participating in (or leading).
5 posts
• Page 1 of 1